Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has been assigned a consensus rating of “Buy” from the fourteen analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $34.20.
Several analysts have weighed in on DRNA shares. Berenberg Bank initiated coverage on Dicerna Pharmaceuticals in a research note on Thursday, March 19th. They set a “buy” rating and a $35.00 price target on the stock. ValuEngine upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd. BidaskClub upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, June 23rd. B. Riley restated a “buy” rating and set a $30.00 price target on shares of Dicerna Pharmaceuticals in a research note on Monday, June 15th. Finally, Royal Bank of Canada began coverage on Dicerna Pharmaceuticals in a research note on Tuesday, May 12th. They issued an “outperform” rating and a $35.00 price objective on the stock.
NASDAQ:DRNA traded up $0.70 during trading hours on Tuesday, hitting $25.42. 13,345 shares of the company traded hands, compared to its average volume of 836,181. The company has a market cap of $1.86 billion, a PE ratio of -14.95 and a beta of 1.85. Dicerna Pharmaceuticals has a one year low of $11.75 and a one year high of $27.68. The company has a quick ratio of 2.90, a current ratio of 2.90 and a debt-to-equity ratio of 0.12. The firm’s 50-day simple moving average is $22.22 and its 200-day simple moving average is $20.89.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.28 by ($0.59). The business had revenue of $34.03 million for the quarter, compared to the consensus estimate of $59.61 million. Dicerna Pharmaceuticals had a negative return on equity of 74.79% and a negative net margin of 213.04%. As a group, equities research analysts expect that Dicerna Pharmaceuticals will post 0.18 EPS for the current year.
In related news, CFO John B. Green sold 20,469 shares of the company’s stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $19.95, for a total transaction of $408,356.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Bob D. Brown sold 9,670 shares of the company’s stock in a transaction dated Friday, June 19th. The stock was sold at an average price of $25.00, for a total transaction of $241,750.00. Following the sale, the insider now directly owns 14,670 shares of the company’s stock, valued at approximately $366,750. The disclosure for this sale can be found here. Insiders sold 119,960 shares of company stock worth $2,647,560 over the last 90 days. 11.30% of the stock is currently owned by corporate insiders.
Several hedge funds have recently bought and sold shares of DRNA. US Bancorp DE purchased a new stake in Dicerna Pharmaceuticals in the 4th quarter worth about $27,000. Victory Capital Management Inc. increased its holdings in shares of Dicerna Pharmaceuticals by 339.9% in the 4th quarter. Victory Capital Management Inc. now owns 41,132 shares of the biopharmaceutical company’s stock valued at $812,000 after acquiring an additional 31,782 shares during the period. Principal Financial Group Inc. purchased a new position in Dicerna Pharmaceuticals during the 4th quarter worth $220,000. Rhumbline Advisers grew its stake in Dicerna Pharmaceuticals by 2.9% during the 4th quarter. Rhumbline Advisers now owns 74,804 shares of the biopharmaceutical company’s stock worth $1,648,000 after buying an additional 2,114 shares during the last quarter. Finally, Swiss National Bank grew its stake in Dicerna Pharmaceuticals by 2.0% during the 4th quarter. Swiss National Bank now owns 98,100 shares of the biopharmaceutical company’s stock worth $2,161,000 after buying an additional 1,900 shares during the last quarter. 82.78% of the stock is owned by hedge funds and other institutional investors.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Further Reading: What is a front-end load?
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.